These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30734609)

  • 1. Structure-guided design of anti-cancer ribonucleotide reductase inhibitors.
    Misko TA; Liu YT; Harris ME; Oleinick NL; Pink J; Lee HY; Dealwis CG
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):438-450. PubMed ID: 30734609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.
    Huff SE; Mohammed FA; Yang M; Agrawal P; Pink J; Harris ME; Dealwis CG; Viswanathan R
    J Med Chem; 2018 Feb; 61(3):666-680. PubMed ID: 29253340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.
    Ahmad MF; Alam I; Huff SE; Pink J; Flanagan SA; Shewach D; Misko TA; Oleinick NL; Harte WE; Viswanathan R; Harris ME; Dealwis CG
    Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8241-8246. PubMed ID: 28716944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent ribonucleotide reductase inhibitors: Thiazole-containing thiosemicarbazone derivatives.
    Ertas M; Sahin Z; Bulbul EF; Bender C; Biltekin SN; Berk B; Yurttas L; Nalbur AM; Celik H; Demirayak Ş
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900033. PubMed ID: 31475759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Iminodiacetate-Thiosemicarbazone Hybrids and Their Copper(II) Complexes Are Potential Ribonucleotide Reductase R2 Inhibitors with High Antiproliferative Activity.
    Zaltariov MF; Hammerstad M; Arabshahi HJ; Jovanović K; Richter KW; Cazacu M; Shova S; Balan M; Andersen NH; Radulović S; Reynisson J; Andersson KK; Arion VB
    Inorg Chem; 2017 Mar; 56(6):3532-3549. PubMed ID: 28252952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
    Petrelli R; Meli M; Vita P; Torquati I; Ferro A; Vodnala M; D'Alessandro N; Tolomeo M; Del Bello F; Kusumanchi P; Franchetti P; Grifantini M; Jayaram HN; Hofer A; Cappellacci L
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5304-9. PubMed ID: 25304896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the therapeutic potential of a non-natural nucleotide that inhibits human ribonucleotide reductase.
    Ahmad MF; Wan Q; Jha S; Motea E; Berdis A; Dealwis C
    Mol Cancer Ther; 2012 Oct; 11(10):2077-86. PubMed ID: 22933704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators.
    Ahmad MF; Huff SE; Pink J; Alam I; Zhang A; Perry K; Harris ME; Misko T; Porwal SK; Oleinick NL; Miyagi M; Viswanathan R; Dealwis CG
    J Med Chem; 2015 Dec; 58(24):9498-509. PubMed ID: 26488902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
    Li J; Zheng LM; King I; Doyle TW; Chen SH
    Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleotide reductase inhibitors and future drug design.
    Shao J; Zhou B; Chu B; Yen Y
    Curr Cancer Drug Targets; 2006 Aug; 6(5):409-31. PubMed ID: 16918309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
    Cappellacci L; Franchetti P; Vita P; Petrelli R; Lavecchia A; Jayaram HN; Saiko P; Graser G; Szekeres T; Grifantini M
    J Med Chem; 2008 Jul; 51(14):4260-9. PubMed ID: 18588281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.
    Huff SE; Winter JM; Dealwis CG
    Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and virtual screening towards synthesis of novel substituted thiosemicarbozones as ribonuleotide reductase (RNR) inhibitors with improved cellular trafficking and anticancer activity.
    Gokhale N; Jain S; Yadav M
    Curr Top Med Chem; 2015; 15(1):37-42. PubMed ID: 25579572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
    Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
    Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of human telomerase inhibitors having the core of N-acyl-4,5-dihydropyrazole with anticancer effects.
    Xiao X; Ni Y; Jia YM; Zheng M; Xu HF; Xu J; Liao C
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1508-1511. PubMed ID: 26883149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More potent linear peptide inhibitors of mammalian ribonucleotide reductase.
    Tan C; Gao Y; Kaur J; Cooperman BS
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5301-4. PubMed ID: 15454215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
    Zhou B; Su L; Hu S; Hu W; Yip ML; Wu J; Gaur S; Smith DL; Yuan YC; Synold TW; Horne D; Yen Y
    Cancer Res; 2013 Nov; 73(21):6484-93. PubMed ID: 24072748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fragment-like approach to PYCR1 inhibition.
    Milne K; Sun J; Zaal EA; Mowat J; Celie PHN; Fish A; Berkers CR; Forlani G; Loayza-Puch F; Jamieson C; Agami R
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2626-2631. PubMed ID: 31362921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.